Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Keynote-024

- PMLiVE

Moderna/Merck’s cancer vaccine shows promise in high-risk melanoma patients

Nearly 325,000 new cases of melanoma were diagnosed globally in 2020

- PMLiVE

MSD’s Keytruda to be made available in England for advanced cervical cancer patients

Around 2,600 people are diagnosed with cervical cancer each year in England

- PMLiVE

Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer

It is estimated there will be around 66,000 new cases of uterine cancer in the US this year

- PMLiVE

AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer

More than 52,000 men are diagnosed with prostate cancer every year in the UK alone

- PMLiVE

Merck reports positive results for Keytruda combination in malignant pleural mesothelioma

The disease develops in the lungs and accounts for 75% of all cancerous mesothelioma cases

- PMLiVE

Moderna/Merck’s skin cancer therapy given FDA breakthrough therapy designation

Nearly 325,000 new cases of melanoma were diagnosed globally in 2020

- PMLiVE

Merck reports positive results for Keytruda combination in phase 3 gastric cancer trial

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

AstraZeneca and MSD report final overall survival results from prostate cancer study

The combination treatment increased the current patient survival rate by over seven months

- PMLiVE

MSD’s Keytruda plus chemotherapy approved in Scotland for advanced cervical cancer

There were around 604,000 new cases and 342,000 deaths in 2020 from cervical cancer

- PMLiVE

Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer

Endometrial cancer is the sixth most common cancer in women worldwide

- PMLiVE

AZ and MSD launch ‘Never Miss’ for prostate cancer awareness

Prostate cancer is often symptomless and is the second most common cancer in men globally

- PMLiVE

Merck’s Keytruda meets primary endpoint in phase 3 gastric cancer trial

Gastric cancer is the fourth leading cause of cancer death worldwide

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links